Matthew Gornet, MD, on Developing Alternatives to Surgery in Lumbar Degenerative Disc Disease

Video

The spine surgeon from The Orthopedic Center of St. Louis discussed unmet needs in the lumbar DDD population.

“Right now, we have a gap in treatment and the gap is essentially failing conservative care and having no other options besides invasive costly surgery. I believe that the new cellular based treatment from DiscGenics sits right in between those 2 areas, not only from a cost standpoint, but with clinical outcomes, which initially look favorable.”

IDCT (rebonuputemcel), DiscGenics’ allogeneic discogenic progenitor cell therapy, recently demonstrated safety and yielded durable improvements in low back pain, function, quality of life, and pain medication usage by 12 weeks in patients with lumbar degenerative disc disease (DDD) in 2-year data from the phase 1/2 DGX-A01 study (NCT03347708). The FDA also granted IDCT regenerative medicine advanced therapy designation.

CGTLive spoke with investigator Matthew Gornet, MD, spine surgeon at The Orthopedic Center of St. Louis, to learn more about the potential of IDCT to address unmet needs in the lumbar DDD population. He stressed how the cell therapy could offer both cost-savings and clinical benefit advantages in treating the disease.

REFERENCES
1. DiscGenics announces positive two-year clinical data from study of discogenic progenitor cell therapy for degenerative disc disease. News release. DiscGenics. January 23, 2023. https://www.prnewswire.com/news-releases/discgenics-announces-positive-two-year-clinical-data-from-study-of-discogenic-progenitor-cell-therapy-for-degenerative-disc-disease-301728259.html
2. DiscGenics announces FDA regenerative medicine advanced therapy (RMAT) designation granted to IDCT for degenerative disc disease. News release. DiscGenics. January 26, 2023. https://www.discgenics.com/news-posts/2023/1/26/discgenics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-idct-for-degenerative-disc-disease
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.